Philadelphia, PA, United States of America

Saar Gill

This inventor holds 31 USPTO granted patents and 38 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: University of Pennsylvania, Novartis Ag. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Saar Gill. Retrieved from https://idiyas.com/inventor/saar-gill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 31 (Patent Applications = 38)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 12)

EPO Patents = 11 (Patent Applications = 26)

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 231(Granted Patents)

Company Filing History:

31 out of 2,663

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Gene Editing

Cancer Therapies

T Cell Lymphomas

Cytokine Release Syndrome

Immune Effector Cells

Viral Particle

Hematopoietic Stem Cells

Biomarkers

Monocytes

Macrophages

Leukemia

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344657 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2025-07-01),

2. 12227588 - Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias (2025-02-18),

3. 12163119 - Methods and composition for gene delivery using an engineered viral particle (2024-12-10),

4. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),

5. 11884716 - Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells (2024-01-30),

6. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),

7. 11771719 - Methods and compositions for gene editing in hematopoietic stem cells (2023-10-03),

8. 11747346 - Biomarkers predictive of cytokine release syndrome (2023-09-05),

9. 11723927 - Methods and composition for gene delivery using an engineered viral particle (2023-08-15),

10. 11673964 - Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias (2023-06-13),

11. 11591404 - Treatment of cancer using a CD123 chimeric antigen receptor (2023-02-28),

12. 11498954 - Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof (2022-11-15),

13. 11407805 - Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof (2022-08-09),

14. 11359002 - Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof (2022-06-14),

15. 11332511 - Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof (2022-05-17),

Title: Saar Gill: Pioneering Inventor from Philadelphia

Introduction: Saar Gill is a renowned inventor based in Philadelphia, PA, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Saar Gill holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With over two decades of experience in the industry, Saar Gill has worked with leading research institutions and companies to develop cutting-edge solutions that have revolutionized the way we approach complex challenges.

Collaborations: Throughout his career, Saar Gill has collaborated with top universities, tech companies, and medical institutions, fostering a culture of innovation and knowledge-sharing that has led to numerous successful projects and inventions.

Conclusion: Saar Gill's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs, making him a true pioneer in the world of technology and patents.

Profile summary based on public USPTO records.